Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Mylan Inc

Market Cap 19.19B 16.54B 15.22B 14.28B 26.83B 1,814B 27.1B 180B 70.3B 888B 72.02B 70.5B 3,074B P/E Ratio 2026 *
60.3x
P/E Ratio 2027 * 26.1x
Enterprise Value 31.38B 27.05B 24.89B 23.35B 43.86B 2,966B 44.3B 294B 115B 1,452B 118B 115B 5,025B EV / Sales 2026 *
2.12x
EV / Sales 2027 * 2.01x
Free-Float
92.11%
Yield 2026 *
3.09%
Yield 2027 * 3.17%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Tech/Sci/R&D Officer - 15/12/2023
Director TitleAgeSince
Director/Board Member 78 16/11/2020
Director/Board Member 78 16/11/2020
Director/Board Member 62 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.32%-0.18%+37.83%+152.24% 1,010B
-2.16%+1.24%+50.01%+45.87% 580B
-2.70%-2.48%+15.97%+62.66% 402B
-0.46%0.00%+21.28%+19.14% 330B
-1.52%+1.90%+23.73%+34.08% 281B
-1.95%-4.75%+20.15%+14.68% 280B
-0.57%+0.62%-44.67%-47.65% 197B
-1.31%+0.27%+18.74%+57.70% 192B
-0.38%-3.76%+13.02%+59.46% 156B
Average -1.34%+0.84%+17.34%+44.24% 380.97B
Weighted average by Cap. -1.20%+1.04%+26.19%+69.00%

Financials

2026 *2027 *
Net sales 14.77B 12.73B 11.72B 10.99B 20.65B 1,396B 20.86B 139B 54.12B 684B 55.44B 54.27B 2,366B 15.04B 12.96B 11.93B 11.19B 21.02B 1,421B 21.23B 141B 55.08B 696B 56.43B 55.24B 2,408B
Net income 13M 11.2M 10.31M 9.67M 18.17M 1.23B 18.35M 122M 47.61M 602M 48.78M 47.74M 2.08B 498M 429M 395M 370M 695M 47.02B 702M 4.67B 1.82B 23.03B 1.87B 1.83B 79.68B
Net Debt 12.19B 10.5B 9.67B 9.07B 17.04B 1,152B 17.21B 114B 44.64B 564B 45.73B 44.76B 1,952B 11.03B 9.51B 8.75B 8.21B 15.42B 1,042B 15.57B 103B 40.41B 511B 41.39B 40.52B 1,767B
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!